SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Guest Michael)
 

Sökning: WFRF:(Guest Michael) > (2020-2023) > Measurable residual...

Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia : a study by the international Berlin-Frankfurt-Münster study group

van Weelderen, Romy E. (författare)
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
Klein, Kim (författare)
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, Netherlands
Harrison, Christine J. (författare)
Leukemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom
visa fler...
Jiang, Yilin (författare)
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
Abrahamsson, Jonas (författare)
Department of Pediatrics, Institute of Clinical Sciences, Salgrenska University Hospital, Gothenburg, Sweden
Arad-Cohen, Nira (författare)
Pediatric Hemato-Oncology Department, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel
Bart-Delabesse, Emmanuelle (författare)
IUC Toulouse-Oncopole, Laboratoire d'Hématologie secteur Génétique des Hémopathies, Toulouse, France
Buldini, Barbara (författare)
Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padua University, Padua, Italy
De Moerloose, Barbara (författare)
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
Dworzak, Michael N. (författare)
St. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, St Anna Children's Cancer Research Institute, Vienna, Austria
Elitzur, Sarah (författare)
Department of Pediatric Hematology and Oncology, Schneider Children's Medical Center and Tel Aviv University, Tel Aviv, Israel
Fernández Navarro, José M (författare)
Pediatric Oncohematology Unit, Hospital Universitari i Politècnic la Fe, Valencia, Spain
Gerbing, Robert B. (författare)
Department of Statistics, Children's Oncology Group, CA, Monrovia, United States
Goemans, Bianca F. (författare)
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
de Groot-Kruseman, Hester A. (författare)
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; DCOG, Dutch Childhood Oncology Group, Utrecht, Netherlands
Guest, Erin (författare)
Children's Mercy Kansas City, MO, Kansas City, United States
Ha, Shau-Yin (författare)
Department of Pediatrics & Adolescent Medicine, Hong Kong Children's Hospital, Kowloon, Hong Kong
Hasle, Henrik (författare)
Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Kelaidi, Charikleia (författare)
Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece
Lapillonne, Hélène (författare)
Pediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France
Leverger, Guy (författare)
Pediatric Hematology and Oncology Department, Hôpital Armand Trousseau, Paris, France
Locatelli, Franco (författare)
Department of Pediatric Hematology and Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy
Masetti, Riccardo (författare)
Pediatric Oncology and Hematology, University of Bologna, Bologna, Italy
Miyamura, Takako (författare)
Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
Norén-Nyström, Ulrika (författare)
Umeå universitet,Pediatrik
Polychronopoulou, Sophia (författare)
Department of Pediatric Hematology and Oncology, Aghia Sophia Children's Hospital, Athens, Greece
Rasche, Mareike (författare)
Department of Pediatric Hematology and Oncology, University Hospital Essen, Essen, Germany
Rubnitz, Jeffrey E. (författare)
Department of Oncology, St Jude Children's Research Hospital, TN, Memphis, United States
Stary, Jan (författare)
Department of Pediatric Hematology and Oncology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
Tierens, Anne (författare)
Department of Pathobiology and Laboratory Medicine, Toronto General Hospital, University Health Network, ON, Toronto, Canada
Tomizawa, Daisuke (författare)
Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan
Zwaan, C Michel (författare)
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
Kaspers, Gertjan J L (författare)
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
visa färre...
 (creator_code:org_t)
American Society of Clinical Oncology (ASCO), 2023
2023
Engelska.
Ingår i: Journal of Clinical Oncology. - : American Society of Clinical Oncology (ASCO). - 0732-183X .- 1527-7755. ; 41:16, s. 2963-2974
Relaterad länk:
https://doi.org/10.1...
visa fler...
https://umu.diva-por... (primary) (Raw object)
https://urn.kb.se/re...
https://doi.org/10.1...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Purpose: A previous study by the International Berlin-Frankfurt-Münster Study Group (I-BFM-SG) on childhood KMT2A-rearranged (KMT2A-r) AML demonstrated the prognostic value of the fusion partner. This I-BFM-SG study investigated the value of flow cytometry-based measurable residual disease (flow-MRD) and evaluated the benefit of allogeneic stem-cell transplantation (allo-SCT) in first complete remission (CR1) in this disease.Methods: A total of 1,130 children with KMT2A-r AML, diagnosed between January 2005 and December 2016, were assigned to high-risk (n = 402; 35.6%) or non-high-risk (n = 728; 64.4%) fusion partner-based groups. Flow-MRD levels at both end of induction 1 (EOI1) and 2 (EOI2) were available for 456 patients and were considered negative (<0.1%) or positive (≥0.1%). End points were 5-year event-free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS).Results: The high-risk group had inferior EFS (30.3% high risk v 54.0% non-high risk; P < .0001), CIR (59.7% v 35.2%; P < .0001), and OS (49.2% v 70.5%; P < .0001). EOI2 MRD negativity was associated with superior EFS (n = 413; 47.6% MRD negativity v n = 43; 16.3% MRD positivity; P < .0001) and OS (n = 413; 66.0% v n = 43; 27.9%; P < .0001), and showed a trend toward lower CIR (n = 392; 46.1% v n = 26; 65.4%; P = .016). Similar results were obtained for patients with EOI2 MRD negativity within both risk groups, except that within the non-high-risk group, CIR was comparable with that of patients with EOI2 MRD positivity. Allo-SCT in CR1 only reduced CIR (hazard ratio, 0.5 [95% CI, 0.4 to 0.8]; P = .00096) within the high-risk group but did not improve OS. In multivariable analyses, EOI2 MRD positivity and high-risk group were independently associated with inferior EFS, CIR, and OS.Conclusion: EOI2 flow-MRD is an independent prognostic factor and should be included as risk stratification factor in childhood KMT2A-r AML. Treatment approaches other than allo-SCT in CR1 are needed to improve prognosis.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Pediatrik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Pediatrics (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy